A61K49/0433

Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors

This invention relates to novel compounds suitable for labelling or already labelled by .sup.18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

IMAGEABLE POLYMERS

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system

Catalytic radiofluorination

One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to arylammonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the ammonium compound is a tetraaryl ammonium salt. Another aspect of the invention relates to arylsulfonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the sulfonium compound is a triaryl sulfonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.

SETTING OF HARDENABLE BONE SUBSTITUTE

The invention relates to hardenable ceramic bone substitute compositions having improved setting, powders for such compositions and methods for their manufacture and use in medical treatment. More specifically the invention relates to hardenable bone substitute powder and hardenable bone substitute paste with improved setting properties, comprising calcium sulfate and heat-treated hydroxyapatite (passivated HA), which bone substitute is suitable for treatment of disorders of supportive tissue such as bone loss, bone fracture, bone trauma and osteomyelitis.

X-ray imaging contrast media with low iodine concentration and X-ray imaging process

The present invention relates to X-ray examinations and to the improvement of patient safety during such. More specifically the invention relates to X-ray diagnostic compositions having low concentrations of iodine and an optimized amount of electrolytes. The invention further relates to methods of X-ray examinations wherein a body is administered with an X-ray diagnostic composition comprising a low concentration of iodine and irradiated with a radiation dose.

Bolus Imaging
20180168529 · 2018-06-21 ·

A system and method includes detection of a trigger event, automatic injection, in response to detecting the trigger event, of a bolus of contrast medium into a patient volume after expiration of a predetermined injection delay period, automatic acquisition, in response to detecting the trigger event, of a plurality of images after expiration of a predetermined imaging delay period, where two or more of the plurality of images comprise an image of the bolus at respective different locations within vasculature of the patient volume, generation of a composite image based on the plurality of images, the composite image including a representation of the vasculature of the patient volume, and display of the composite image.

DIAGNOSTIC IMAGING AGENT FOR EARLY BONE METASTASIS FROM CANCER

There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[.sup.18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

CONTRAST IMAGING AGENT WITH DISSOLVED GAS-EVOLVING FLUID
20180064830 · 2018-03-08 ·

A diagnostic contrast composition includes a carrier fluid and a non-decaying gas-evolving fluid incorporated in the carrier fluid. The gas-evolving fluid has a vapor pressure sufficient to evolve the gas from a circulatory system within a lung of a patient. The gas-evolving fluid is a composition containing a sufficient quantity of atoms with an atomic number higher than 8 to provide an increased absorption sufficient to increase a Hounsfield Unit measurement in an image in a CT imaging system. The gas-evolving fluid is selected from the group consisting of xenon gas, krypton gas, sulfur hexafluoride, a perfluorocarbon, a brominated perfluorocarbon, and combinations thereof. The carrier fluid is selected from the group consisting of water, saline, saline comprising one or more blood proteins, and saline comprising dissolved lipids.

Imageable polymers

The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalized with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system.

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS

This invention relates to novel compounds suitable for labelling or already labelled by .sup.18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).